New shot for high cholesterol passes first safety test in humans
NCT ID NCT06541457
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-stage trial tested a single injection of HRS-7249 in 48 healthy adults with high cholesterol. The main goal was to check safety and how the drug moves through the body. Participants were randomly assigned to receive either the drug or a placebo, and researchers monitored for side effects. This is a first step to see if the drug might one day help control cholesterol levels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HRS-7249 injection
What this could lead to
If successful, this could lead to a new injectable treatment for high cholesterol, offering a convenient alternative to daily pills.
What could go wrong
This is an early Phase 1 trial with only 48 healthy people, so it is too soon to know if it works or is safe. The drug may cause side effects or fail in later studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HYPERLIPIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, Zhejiang, 310009, China